Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The provided claim is fully consistent with the supplied ZEPBOUND label excerpts for thyroid C-cell tumors, including rodent findings, uncertainty of human relevance, contraindications (MTC/MEN 2), symptom counseling, and the label’s stance that routine calcitonin/ultrasound monitoring has uncertain value with guidance for evaluation if calcitonin is elevated.
Category Scores
Accurate Statements
“RISK OF THYROID C-CELL TUMORS (including MTC risk) is addressed in the ZEPBOUND prescribing information, with rodent findings, unknown human relevance, counseling on symptoms, and discussion of contraindications/monitoring.”
Supported by 5.1 (rodent dose-/duration-dependent thyroid C-cell tumors; unknown human relevance; counseling on thyroid tumor symptoms; routine calcitonin/ultrasound monitoring uncertain value and next steps if calcitonin elevated), 4 Contraindications (personal/family history of MTC or MEN 2), and 17 (patient counseling).
The label states tirzepatide causes thyroid C-cell tumors in rats and that human relevance is unknown.
5.1 and 13.1.
Contraindications include patients with personal or family history of MTC or patients with MEN 2.
4 Contraindications and referenced in 5.1.
Patients are counseled about potential thyroid tumor symptoms (e.g., neck mass, persistent hoarseness, dysphagia, dyspnea).
5.1 and 17.
Routine monitoring with serum calcitonin and/or thyroid ultrasound is of uncertain value for early detection; if calcitonin is elevated, further evaluation is recommended.
5.1.
Unsupported Statements
“Risk of Thyroid C-cell tumors (including MTC risk) is addressed … with … discussion of … monitoring.”
Partially unsupported in phrasing if interpreted as endorsing monitoring as a routine recommendation; however the label explicitly says routine monitoring has uncertain value and describes evaluation if calcitonin is elevated. The statement remains broadly supported but slightly imprecise about intent of monitoring.
Contradictions
Important Omissions
The claim does not explicitly mention that routine calcitonin has low specificity and that high background incidence of thyroid disease may lead to unnecessary procedures (details within 5.1).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
No contradictions to the label. The statement aligns with key labeled safety elements for thyroid C-cell tumor risk, including contraindications and symptom counseling. Minor imprecision is limited to how “monitoring” is characterized, but it does not overturn the label’s uncertain-value framing.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Slight imprecision regarding “monitoring” (the label emphasizes uncertain value and discusses evaluation if calcitonin is elevated, rather than endorsing routine screening).
Suggested Improvement
Rephrase to reflect that routine calcitonin/thyroid ultrasound monitoring has uncertain value, and that further evaluation is warranted if calcitonin is elevated.